Answers are grounded in this paper and cite their sources.
HIV-specific neutralizing antibodies are crucial for sterilizing immunity but have been difficult to elicit using current vaccine approaches. By contrast, non-neutralizing antibodies that mediate other effector functions are readily induced. Recent data suggest these antibodies may play a significant role in viral load reduction and/or clearance. The interval between viral entry across a mucosal barrier and development of systemic infection provides a timeframe during which these antibodies may impact the outcome of infection. Here we discuss various effector mechanisms mediated by non-neutralizing antibodies and summarize evidence of their contribution to protective efficacy. We suggest that non-neutralizing antibody components be incorporated into vaccine strategies, and predict that further exploration of this area of research will prove fruitful for HIV vaccine development.
No takes yet. Share an insight, caveat, or question.
Florese et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: